FIELD: medicine.
SUBSTANCE: invention relates to medications and deals with pharmaceutical composition with prolonged release of hydralazine for cancer treatment, which differs in that it contains: (a) from 10% to 70% of hydralazine hydrochloride as active ingredient; (b) from 3% to 50% of one or more than one polymer, limiting the rate of said active ingredient release; (c) from 15% to 40% of diluent; (d) from 5 to 20% of hydrophilic polymer, limiting release rate; and (e) from 0.1 to 2% of lubricating agent, where said composition is applied at release rate to 7.58 mg/h inclusive during 24 hours.
EFFECT: invention is aimed at creation of medicinal form with prolonged release of hydralazine, ensuring constant concentration of active principle in blood.
3 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FORMULATIONS OF LORAZEPAM WITH SUSTAINED RELEASE | 2014 |
|
RU2678324C2 |
| TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
| LAMOTRIGINE-BASED COMPOSITIONS OF PROLONGED RELEASE | 2003 |
|
RU2325163C2 |
| COMPOSITION AS MULTIPLE PARTICLES WITH MODIFIED RELEASE | 1999 |
|
RU2236847C2 |
| COMPOSITIONS AND METHODS FOR TREATING CANCER | 2017 |
|
RU2770081C2 |
| CHRONOTHERAPEUTIC PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2571067C2 |
| MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
| COMPOSITION INHIBITING SECRETION OF ACID IN STOMACH | 2003 |
|
RU2340358C2 |
| PHARMACEUTICAL COMPOSITION OF METFORMIN WITH PROLONGED RELEASE AND METHOD OF ITS OBTAINING | 2006 |
|
RU2433821C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
